54 research outputs found
Drug âclickingâ on cell-penetrating fluorescent nanoparticles for in cellulo chemical proteomics
Chemical
proteomics approaches are widely used to identify molecular
targets of existing or novel drugs. This manuscript describes the
development of a straightforward approach to conjugate azide-labeled
drugs via click chemistry to alkyne-tagged cell-penetrating fluorescent
nanoparticles as a novel tool to study target engagement and/or identification
inside living cells. A modification of the Baeyer test for alkynes
allows monitoring the CuÂ(I)-catalyzed azideâalkyne cycloaddition
(CuAAC) reaction, guaranteeing the presence of the drug on the solid
support. As a proof of concept, the conjugation of the promiscuous
kinase inhibitor dasatinib to Cy5-labeled nanoparticles is presented.
Dasatinib-decorated fluorescent nanoparticles efficiently inhibited
its protein target SRC in vitro, entered cancer cells,
and colocalized with SRC in cellulo
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor
Bioorthogonal
uncaging strategies have recently emerged as an experimental therapeutic
approach to control drug release. Herein we report a novel masking
strategy that enables to modulate the metal chelating properties of
hydroxamic acid groups by bioorthogonal chemistry using Pd-functionalized
resins. This novel approach allowed to devise an inactive precursor
of the histone deacetylase inhibitor vorinostat that was efficiently
uncaged by heterogeneous Pd catalysis in cell culture models of glioma
and lung cancer
Synthesis and characterization of a click-assembled 18-atom macrocycle that displays selective AXL kinase inhibitory activity
A novel macrocyclic construct consisting of a pyrazolopyrimidine scaffold concatenated to a benzene ring
through two triazoles has been developed to investigate uncharted chemical space with bioactive potential. The 18-atom
macrocycle was assembled via a double copper-catalyzed alkyneâazide cycloaddition (CuAAC) reaction between 1,3-
bis(azidomethyl)benzene and a bis-propargylated pyrazolo[3,4-d]pyrimidine core. The resulting macrocycle was functionalized
further into a multicyclic analog that displays selective inhibitory activity against the receptor tyrosine kinase AXL.O.C.-L. and B.L. thank Spain Ministry of Education, Culture
and Sport and the Erasmus + Traineeship programme for
funding, respectively. C.T. thanks the CMVM for a Principalâs
Scholarship. F.F. acknowledges support from Universidad de
Granada. SHM and AU-B are grateful to Scottish Power and
CRUK for funding
Development of potent inhibitors of receptor tyrosine kinases by ligand-based drug design and target-biased phenotypic screening
Pyrazolopyrimidines with potent antiproliferative
properties were
developed by an adaptive strategy that applies ligand-based design
and phenotypic screening iteratively and is informed by biochemical
assays. To drive development toward specific oncopathways, compounds
were tested against cancer cells that overexpress, or not, AXL kinase.
Identified phenotypic hits were found to inhibit oncotargets AXL,
RET, and FLT3. Subsequent optimization generated antiproliferative
lead compounds with unique selectivity profiles, including selective
AXL inhibitors and a highly potent inhibitor of FLT3
Design and manufacture of functional catalyst-carrier structures for the bioorthogonal activation of anticancer agents
Novel palladium (Pd)-loaded titanium (Ti) devices with high biocompatibility and catalytic activity were prepared using a range of fabrication methods such as powder metallurgy (i.e. sintering with and without space-holder), sputtering, pulsed laser deposition and supersonic cluster beam deposition. The surface of the Ti-[Pd] devices were physico-chemically characterised to confirm the non-alloyed state of the Pd coating onto the titanium substrate. The Pd thickness was optimised to achieve maximum surface area (i.e. maximum catalytic effect) using the minimum amount of material in each method for cost effective production. The catalytic response of the different Ti-[Pd] devices was evaluated under biocompatible conditions by employing an off-on Pd-activatable fluorescent probe. The most robust coating of Pd was produced by an optimised magnetron sputtering method. The sputtered Ti-[Pd] devices were selected to induce the bioorthogonal uncaging of the anticancer drug Vorinostat from a pharmacologically-inactive Pd-activatable precursor in cancer cell culture, demonstrating the capacity of these devices to mediate a local anti-tumour effect via in-situ release of a clinically approved drug. This approach is the first step towards surgically implantable devices that could facilitate targeting affected areas with high spatial selectivity, improving pharmacological activity and reducing systemic side effects through localised treatment directly at the cancer site
- âŠ